{"id":"https://openalex.org/W4362545818","doi":"https://doi.org/10.1158/2326-6066.c.6548582.v1","title":"Data from Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab","display_name":"Data from Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362545818","doi":"https://doi.org/10.1158/2326-6066.c.6548582.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.c.6548582.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548582.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548582.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/2326-6066.c.6548582.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047177507","display_name":"Jeffrey S. Weber","orcid":"https://orcid.org/0000-0002-4962-2957","observed_orcids":["https://orcid.org/0000-0002-4962-2957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey Weber","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026672076","display_name":"Geoffrey Thomas Gibney","orcid":"https://orcid.org/0000-0002-5401-8498","observed_orcids":["https://orcid.org/0000-0002-5401-8498"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geoffrey Gibney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012911914","display_name":"Ragini Reiney Kudchadkar","orcid":"https://orcid.org/0000-0001-9070-5052","observed_orcids":["https://orcid.org/0000-0001-9070-5052","https://orcid.org/0009-0007-1703-7845"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ragini Kudchadkar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076666539","display_name":"Bin Yu","orcid":"https://orcid.org/0000-0001-7796-7314","observed_orcids":["https://orcid.org/0000-0001-7796-7314"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bin Yu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052521597","display_name":"Pingyan Cheng","orcid":"https://orcid.org/0009-0003-0205-1418","observed_orcids":["https://orcid.org/0009-0003-0205-1418"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pingyan Cheng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068571006","display_name":"Alberto J. Martinez","orcid":"https://orcid.org/0000-0002-9061-8650","observed_orcids":["https://orcid.org/0000-0002-9061-8650"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alberto J. Martinez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062103438","display_name":"Jodie Kroeger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jodie Kroeger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006339007","display_name":"Allison L. Richards","orcid":"https://orcid.org/0000-0003-2312-2302","observed_orcids":["https://orcid.org/0000-0003-2312-2302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allison Richards","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067274155","display_name":"Lori McCormick","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lori McCormick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014833866","display_name":"Valerie E. Moberg","orcid":"https://orcid.org/0009-0002-1145-0026","observed_orcids":["https://orcid.org/0009-0002-1145-0026"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Valerie Moberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023605565","display_name":"Heather Cronin","orcid":"https://orcid.org/0000-0001-9204-7241","observed_orcids":["https://orcid.org/0000-0001-9204-7241"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Heather Cronin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102319325","display_name":"Xiuhua Zhao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiuhua Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055925608","display_name":"Michael J. Schell","orcid":"https://orcid.org/0000-0003-4594-6601","observed_orcids":["https://orcid.org/0000-0003-4594-6601"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Schell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5006097304","display_name":"Y. Ann Chen","orcid":"https://orcid.org/0000-0003-1468-3490","observed_orcids":["https://orcid.org/0000-0003-1468-3490","https://orcid.org/0000-0003-4936-8060"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yian Ann Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9380000233650208},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9580000042915344},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9200000166893005},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9010000228881836},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7919999957084656},{"id":"https://openalex.org/keywords/multipeptide-vaccine","display_name":"multipeptide vaccine","score":0.781000018119812},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6470000147819519},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8889999985694885},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6140000224113464},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.3540000021457672}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9883793592453003},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.938073992729187},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8670346736907959},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.644256591796875},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.631722092628479},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5376118421554565},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5324702262878418},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43090584874153137},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40720218420028687},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3229408264160156},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.21501445770263672},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.19044890999794006},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.07586279511451721},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2326-6066.c.6548582.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548582.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548582.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.c.6548582.v1","doi":"https://doi.org/10.1158/2326-6066.c.6548582.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2326-6066.c.6548582.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2267367070","https://openalex.org/W2135707184","https://openalex.org/W2463257517","https://openalex.org/W2286032567","https://openalex.org/W2133036011","https://openalex.org/W2765564427","https://openalex.org/W2305646079","https://openalex.org/W4415313449","https://openalex.org/W2945885428","https://openalex.org/W2938997009"],"abstract_inverted_index":{"Abstract":[0],"The":[1,83,94,146],"checkpoint":[2],"inhibitor":[3],"nivolumab":[4,58,162,217],"is":[5],"active":[6],"in":[7,25,54,144,199],"patients":[8,28,56,88,116,139,148,201,220],"with":[9,29,77,149,159,164,189,203],"metastatic":[10],"melanoma":[11],"who":[12,38],"have":[13],"failed":[14],"ipilimumab.":[15,45],"In":[16],"this":[17],"phase":[18],"I/II":[19],"study,":[20],"we":[21],"assessed":[22],"nivolumab's":[23],"safety":[24,196],"92":[26],"ipilimumab-refractory":[27,87,138,200],"unresectable":[30],"stage":[31],"III":[32],"or":[33,78,171,174,228],"IV":[34],"melanoma,":[35],"including":[36],"those":[37],"experienced":[39],"grade":[40,151,206],"3\u20134":[41,152,207],"drug-related":[42],"toxicity":[43,153],"to":[44,74,154],"We":[46],"report":[47],"long-term":[48,195],"survival,":[49],"response":[50,84,98],"duration,":[51],"and":[52,108,127,133,137,194,219],"biomarkers":[53],"these":[55],"after":[57],"treatment":[59,238],"(3":[60],"mg/kg)":[61],"every":[62,69],"2":[63,75],"weeks":[64,71],"for":[65,72,86,120],"24":[66,178,231],"weeks,":[67],"then":[68],"12":[70],"up":[73,119],"years,":[76],"without":[79],"a":[80,121,222],"multipeptide":[81],"vaccine.":[82],"rate":[85,225],"was":[89,99,105,112,157],"30%":[90],"(95%":[91,166],"CI,":[92,167],"21%\u201341%).":[93],"median":[95,102,109,122],"duration":[96],"of":[97,123,182,216,226,245],"14.6":[100],"months,":[101,107,114],"progression-free":[103],"survival":[104,111,129,193],"5.3":[106],"overall":[110,224],"20.6":[113],"when":[115],"were":[117,131,187,197,213],"followed":[118],"16":[124],"months.":[125],"One-":[126],"2-year":[128],"rates":[130],"68.4%":[132],"31.2%,":[134],"respectively.":[135],"Ipilimumab-na\u00efve":[136],"showed":[140],"no":[141],"significant":[142],"difference":[143],"survival.":[145,191],"21":[147],"prior":[150],"ipilimumab":[155,212],"that":[156],"managed":[158],"steroids":[160],"tolerated":[161],"well,":[163],"62%":[165],"38%\u201382%)":[168],"having":[169],"complete":[170],"partial":[172],"responses":[173],"stabilized":[175],"disease":[176],"at":[177,230],"weeks.":[179,232],"High":[180],"numbers":[181,236],"myeloid-derived":[183],"suppressor":[184],"cells":[185],"(MDSC)":[186],"associated":[188],"poor":[190],"Thus,":[192],"excellent":[198],"treated":[202],"nivolumab.":[204,246],"Prior":[205],"immune-related":[208],"adverse":[209],"effects":[210],"from":[211],"not":[214],"indicative":[215],"toxicities,":[218],"had":[221],"high":[223],"remission":[227],"stability":[229],"Prospectively":[233],"evaluating":[234],"MDSC":[235],"before":[237],"could":[239],"help":[240],"assess":[241],"the":[242],"expected":[243],"benefit":[244],"Cancer":[247],"Immunol":[248],"Res;":[249],"4(4);":[250],"345\u201353.":[251],"\u00a92016":[252],"AACR.":[253]},"counts_by_year":[],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2023-04-06T00:00:00"}